David has over twenty years experience in a variety of private equity, venture capital and operational roles. He was instrumental in the successful development of venture businesses at 3i and MVM. As an investor he was responsible for successful investments in Cambridge Antibody Technology, Acambis and Oxford GlycoSciences and was also Chairman of Domantis for five years from its inception. Prior to his current range of board and advisory roles he was Chief Business Officer at Evotec, a Deutsche Borse and NASDAQ-listed business.
Dr Mark Warne
Mark has been with IP Group since 2008 developing and commercialising healthcare technology innovations primarily from research intensive universities. Since 2012 he has led IP Groupâ€™s life sciences team and is a member of its therapeutics investment committee. Mark currently represents IP Group on the Boards of a number of its life science portfolio companies. He joined IP Group from pre-clinical drug discovery CRO, Exelgen, where he was managing director. Mark spent eight years at Exelgen (formerly Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry.
Dr Matthew Frohn
Matthew graduated from Oxford Brookes University with a degree in Cell and Molecular Biology followed by a D.Phil in Biochemistry from Oxford University. He worked on research collaborations with Astra Zeneca, and a short research post with a British Biotech subsidiary before joining Oxford Technology Management in 1999, the manager of the Oxford Technology VCTs. He is particularly involved with its life science investments.
Professor Martin Noble
Martin is an experienced protein crystallographer and structural biochemist with a strong publication record in these fields. He is also the author and co-author of software packages used in these areas and has considerable experience in supervising and directing biophysical research projects of this nature. Professor Noble is joint holder of three patents relating to anti-cancer drug design, of which two were jointly developed with AstraZeneca.
Dr John Sinclair
John followed a degree in chemistry and a doctorate in molecular pharmacology at Oxford University with 15 years of research at the Laboratory of Molecular Biophysics in the Universityâ€™s Department of Biochemistry. He has extensive experience in protein design, molecular biology, biochemistry, crystallization and crystallographic structure determination. He is joint inventor of the Crysalin technology and has led research in this area since the initial patent was filed in 2003. John moved from the University to Crysalin Ltd. in 2012.
Dr. Ceri Lewis
Ceri Lewis has over 25 years experience working in the Pharmaceutical Industry. He has an extensive background in technology development, introducing many new developments into the businesses he operated in. Throughout his career he has worked extensively in protein expression, protein biochemistry, protein mass spectrometry and structural biology. Prior to joining Crysalin he was Director of Protein Expression and Biochemistry at GlaxoSmithKline.
James joined Isis Innovation Ltd in April 2003 to manage the Universityâ€™s equity stakes in spin-out companies and joined OSEM on its formation in August 2008 with an expanded and more proactive role. Prior to Isis , James worked in the private equity group at Abbey National Treasury Services as a member of a team of 11 responsible for commitments of Â£1.9bn; Jamesâ€™s particular responsibility was for technology venture investments. He has also been a member of the Strategic Advisory Board of funds managed by Advent Venture Partners and Avlar BioVentures. James gained his first degree in Engineering Science at Oxford University, following which he trained and worked as a software engineer, initially with Marconi Underwater Systems. He gained an MBA from Cranfield in 1990 and has over 17 years of experience in venture capital as both investor and adviser.